Skip to main content

Table 2 Recent studies concerning CPAP and surfactant administration

From: Exogenous surfactant therapy in 2013: what is next? who, when and how should we treat newborn infants in the future?

Study (ref) Year N Population Outcome Groups
COIN Trial (78) 2008 610 25-28 wks   CPAP Systematic intubation
     Death or BPD 33.9% 38.9%
     Intubation 46% 100%
     Selective surfactant 38%*** 77%
     Pneumothorax 9%*** 3%
Rojas et al. (79) 2009 279 27-31 wks   CPAP Intubation-early surfactant-extubation
     Need for MV 39%* 26%
     Pneumothorax 9% 2%
     Rescue surfactant 26%** 12%
     BPD at 36 wks PMA 59% 49%
CURPAP Trial (80) 2010 208 25-28 wks   CPAP Early selective Surfactant Prophylactic surfactant
     Need for MV 33% 31.4%
     Death at 36 wks PMA 10.7% 8.6%
     Pneumothorax 1% 6.7%
     BPD 11.7% 14.3%
SUPPORT Trial (81) 2010 1316 24-28 wks   CPAP Intubation-early surfactant use
     Death or BPD 48.7% 54.1%
     Surfactant use 67.1%*** 98.9%
     Air leak 6.8% 7.4%
Dunn et al. (82) 2011 648 26-29 wks   CPAP Selective surfactant Prophylactic surfactant Intubation-early surfactant-extubation
     Surfactant use 14.8%*** 98.6% 98.2%
     Death or BPD 30.5% 36.5% 28.5%
     Pneumothorax 5.4% 4.8% 3.2%
  1. BPD=bronchopulmonary dysplasia, PMA=postmenstrual age, MV=mechanical ventilation; wks: weeks of gestation.
  2. *:p<0.05; **:p<0.01; ***:p<0.001.